for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chimerix Inc

CMRX.OQ

Latest Trade

5.72USD

Change

-0.04(-0.69%)

Volume

160,988

Today's Range

5.66

 - 

5.78

52 Week Range

2.54

 - 

11.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.76
Open
5.74
Volume
160,988
3M AVG Volume
14.72
Today's High
5.78
Today's Low
5.66
52 Week High
11.54
52 Week Low
2.54
Shares Out (MIL)
86.25
Market Cap (MIL)
496.80
Forward P/E
-4.55
Dividend (Yield %)
--

Next Event

Q3 2021 Chimerix Inc Earnings Release

Latest Developments

More

FDA Says Approved Tembexa (Brincidofovir) To Treat Smallpox

Chimerix Inc Files For Potential Mixed Shelf Offering; Size Not Disclosed

Chimerix Reports First Quarter 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chimerix Inc

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.

Industry

Biotechnology & Drugs

Contact Info

2505 Meridian Pkwy Ste 100

DURHAM, NC

27713-2288

United States

+1.919.8061074

http://www.chimerix.com/

Executive Leadership

Martha J. Demski

Independent Chairman of the Board

Michael A. Sherman

President, Chief Executive Officer, Director

Michael T. Andriole

Chief Financial Officer, Chief Business Officer

Allen Melemed

Chief Medical Officer

Catherine L. Gilliss

Independent Director

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.430

2019

-2.030

2020

-0.700

2021(E)

-1.266
Price To Earnings (TTM)
--
Price To Sales (TTM)
109.07
Price To Book (MRQ)
4.17
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.75
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-127.29
Return on Equity (TTM)
-111.32

Latest News

Latest News

BRIEF-Chimerix Reports Q1 Loss Per Share $0.17

* CHIMERIX REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

BRIEF-Chimerix Announces Initiation Of Phase 2/3 Study Of DSTAT In Acute Lung Injury For Patients With Severe COVID-19

* CHIMERIX ANNOUNCES INITIATION OF A PHASE 2/3 STUDY OF DSTAT IN ACUTE LUNG INJURY FOR PATIENTS WITH SEVERE COVID-19

BRIEF-Chimerix Receives FDA Clearance For Rolling Submission Of New Drug Application For Brincidofovir As A Medical Countermeasure For Smallpox

* CHIMERIX RECEIVES FDA CLEARANCE FOR ROLLING SUBMISSION OF NEW DRUG APPLICATION FOR BRINCIDOFOVIR AS A MEDICAL COUNTERMEASURE FOR SMALLPOX

BRIEF-Chimerix Reports Q4 Loss Per Share Of $0.06

* BRINCIDOFOVIR PRE-NDA MEETING SCHEDULED WITH FDA, ON TRACK FOR MID-2020 NDA FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up